Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay
Open Access
- 28 January 2009
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 38
Abstract
Previous data suggest that lipophilic statins such as fluvastatin and N-bisphosphonates such as zoledronic acid, both inhibitors of the mevalonate metabolic pathway, have anti-cancer effectsin vitroand in patients. We have examined the effect of fluvastatin alone and in combination with zoledronic acid in the ATP-based tumour chemosensitivity assay (ATP-TCA) for effects on breast and ovarian cancer tumour-derived cells. Both zoledronic acid and fluvastatin showed activity in the ATP-TCA against breast and ovarian cancer, though fluvastatin alone was less active, particularly against breast cancer. The combination of zoledronic acid and fluvastatin was more active than either single agent in the ATP-TCA with some synergy against breast and ovarian cancer tumour-derived cells. Sequential drug experiments showed that pre-treatment of ovarian tumour cells with fluvastatin resulted in decreased sensitivity to zoledronic acid. Addition of mevalonate pathway components with zoledronic acid with or without fluvastatin showed little effect, while mevalonate did reduced inhibition due to fluvastatin. These data suggest that the combination of zoledronic acid and fluvastatin may have activity against breast and ovarian cancer based on direct anti-cancer cell effects. A clinical trial to test this is in preparation.Keywords
This publication has 26 references indexed in Scilit:
- Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growthAnti-Cancer Drugs, 2008
- Effect of culture conditions on the chemosensitivity of ovarian cancer cell linesAnti-Cancer Drugs, 2006
- Synergistic antimyeloma effects of zoledronate and simvastatinAnti-Cancer Drugs, 2006
- Lonafarnib in cancer therapyExpert Opinion on Investigational Drugs, 2006
- Zoledronic Acid (Zometa®) Enhances the Cytotoxic Effect of Gemcitabine and Fluvastatin: In vitro Isobologram Studies with Conventional and Nonconventional Cytotoxic AgentsOncology, 2006
- Bisphosphonates: Preclinical ReviewThe Oncologist, 2004
- Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivoBlood, 2003
- Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type IJournal of Biological Chemistry, 1997
- Uniform characterization of potentiation in simple and complex situations when agents bind to different molecular sitesCanadian Journal of Physiology and Pharmacology, 1995
- All ras proteins are polyisoprenylated but only some are palmitoylatedCell, 1989